nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—CYP2D6—Alzheimer's disease	0.296	1	CbGaD
Brompheniramine—CYP2B6—Memantine—Alzheimer's disease	0.121	0.205	CbGbCtD
Brompheniramine—CYP2D6—Rivastigmine—Alzheimer's disease	0.084	0.143	CbGbCtD
Brompheniramine—CYP2C19—Memantine—Alzheimer's disease	0.0766	0.13	CbGbCtD
Brompheniramine—CYP2C9—Donepezil—Alzheimer's disease	0.0735	0.125	CbGbCtD
Brompheniramine—CYP2D6—Donepezil—Alzheimer's disease	0.0672	0.114	CbGbCtD
Brompheniramine—CYP3A4—Rivastigmine—Alzheimer's disease	0.0534	0.0907	CbGbCtD
Brompheniramine—CYP2D6—Galantamine—Alzheimer's disease	0.0433	0.0735	CbGbCtD
Brompheniramine—CYP3A4—Donepezil—Alzheimer's disease	0.0427	0.0725	CbGbCtD
Brompheniramine—CYP3A4—Galantamine—Alzheimer's disease	0.0275	0.0467	CbGbCtD
Brompheniramine—CHRM4—nervous system—Alzheimer's disease	0.00102	0.0423	CbGeAlD
Brompheniramine—CHRM2—forebrain—Alzheimer's disease	0.00101	0.0418	CbGeAlD
Brompheniramine—CHRM4—central nervous system—Alzheimer's disease	0.000984	0.0407	CbGeAlD
Brompheniramine—CHRM2—telencephalon—Alzheimer's disease	0.000929	0.0384	CbGeAlD
Brompheniramine—CHRM1—forebrain—Alzheimer's disease	0.000919	0.038	CbGeAlD
Brompheniramine—CHRM1—telencephalon—Alzheimer's disease	0.000846	0.035	CbGeAlD
Brompheniramine—CHRM3—forebrain—Alzheimer's disease	0.000823	0.034	CbGeAlD
Brompheniramine—CHRM5—nervous system—Alzheimer's disease	0.000799	0.033	CbGeAlD
Brompheniramine—CHRM4—brain—Alzheimer's disease	0.000781	0.0323	CbGeAlD
Brompheniramine—CHRM5—central nervous system—Alzheimer's disease	0.000769	0.0318	CbGeAlD
Brompheniramine—CHRM3—telencephalon—Alzheimer's disease	0.000757	0.0313	CbGeAlD
Brompheniramine—KCNH2—forebrain—Alzheimer's disease	0.00073	0.0302	CbGeAlD
Brompheniramine—KCNH2—telencephalon—Alzheimer's disease	0.000671	0.0277	CbGeAlD
Brompheniramine—CHRM5—brain—Alzheimer's disease	0.000611	0.0252	CbGeAlD
Brompheniramine—HRH1—forebrain—Alzheimer's disease	0.000585	0.0242	CbGeAlD
Brompheniramine—CHRM2—nervous system—Alzheimer's disease	0.000548	0.0227	CbGeAlD
Brompheniramine—HRH1—telencephalon—Alzheimer's disease	0.000538	0.0222	CbGeAlD
Brompheniramine—CHRM2—central nervous system—Alzheimer's disease	0.000528	0.0218	CbGeAlD
Brompheniramine—CYP2E1—telencephalon—Alzheimer's disease	0.000517	0.0214	CbGeAlD
Brompheniramine—CHRM1—nervous system—Alzheimer's disease	0.000499	0.0206	CbGeAlD
Brompheniramine—CHRM1—central nervous system—Alzheimer's disease	0.000481	0.0199	CbGeAlD
Brompheniramine—CHRM3—nervous system—Alzheimer's disease	0.000447	0.0185	CbGeAlD
Brompheniramine—CYP2D6—forebrain—Alzheimer's disease	0.000445	0.0184	CbGeAlD
Brompheniramine—CHRM3—central nervous system—Alzheimer's disease	0.00043	0.0178	CbGeAlD
Brompheniramine—CHRM2—brain—Alzheimer's disease	0.000419	0.0173	CbGeAlD
Brompheniramine—CYP2D6—telencephalon—Alzheimer's disease	0.000409	0.0169	CbGeAlD
Brompheniramine—KCNH2—nervous system—Alzheimer's disease	0.000396	0.0164	CbGeAlD
Brompheniramine—Mepyramine—CYP2D6—Alzheimer's disease	0.000386	0.171	CrCbGaD
Brompheniramine—CHRM1—brain—Alzheimer's disease	0.000382	0.0158	CbGeAlD
Brompheniramine—KCNH2—central nervous system—Alzheimer's disease	0.000381	0.0158	CbGeAlD
Brompheniramine—KCNH2—cerebellum—Alzheimer's disease	0.000373	0.0154	CbGeAlD
Brompheniramine—Tripelennamine—CYP2D6—Alzheimer's disease	0.000357	0.158	CrCbGaD
Brompheniramine—CHRM3—brain—Alzheimer's disease	0.000341	0.0141	CbGeAlD
Brompheniramine—CYP2B6—nervous system—Alzheimer's disease	0.000325	0.0134	CbGeAlD
Brompheniramine—HRH1—nervous system—Alzheimer's disease	0.000317	0.0131	CbGeAlD
Brompheniramine—CYP2B6—central nervous system—Alzheimer's disease	0.000313	0.0129	CbGeAlD
Brompheniramine—HRH1—central nervous system—Alzheimer's disease	0.000306	0.0126	CbGeAlD
Brompheniramine—CYP2E1—nervous system—Alzheimer's disease	0.000305	0.0126	CbGeAlD
Brompheniramine—KCNH2—brain—Alzheimer's disease	0.000303	0.0125	CbGeAlD
Brompheniramine—Chlorphenamine—SLC6A4—Alzheimer's disease	0.000295	0.131	CrCbGaD
Brompheniramine—CYP2E1—central nervous system—Alzheimer's disease	0.000294	0.0121	CbGeAlD
Brompheniramine—CYP2E1—cerebellum—Alzheimer's disease	0.000287	0.0119	CbGeAlD
Brompheniramine—Tolterodine—CYP2D6—Alzheimer's disease	0.000284	0.126	CrCbGaD
Brompheniramine—CYP2C8—brain—Alzheimer's disease	0.000277	0.0115	CbGeAlD
Brompheniramine—CYP2B6—brain—Alzheimer's disease	0.000248	0.0103	CbGeAlD
Brompheniramine—CYP3A4—nervous system—Alzheimer's disease	0.000245	0.0101	CbGeAlD
Brompheniramine—Carbinoxamine—CYP2D6—Alzheimer's disease	0.000244	0.108	CrCbGaD
Brompheniramine—HRH1—brain—Alzheimer's disease	0.000243	0.01	CbGeAlD
Brompheniramine—CYP2D6—nervous system—Alzheimer's disease	0.000242	0.00999	CbGeAlD
Brompheniramine—CYP3A4—central nervous system—Alzheimer's disease	0.000236	0.00977	CbGeAlD
Brompheniramine—CYP2E1—brain—Alzheimer's disease	0.000233	0.00964	CbGeAlD
Brompheniramine—CYP2D6—central nervous system—Alzheimer's disease	0.000233	0.00961	CbGeAlD
Brompheniramine—CYP2D6—cerebellum—Alzheimer's disease	0.000227	0.0094	CbGeAlD
Brompheniramine—Chlorphenamine—CYP2D6—Alzheimer's disease	0.000207	0.092	CrCbGaD
Brompheniramine—Diphenhydramine—PTGS1—Alzheimer's disease	0.000207	0.0917	CrCbGaD
Brompheniramine—CYP2D6—brain—Alzheimer's disease	0.000185	0.00763	CbGeAlD
Brompheniramine—Diphenhydramine—CYP2D6—Alzheimer's disease	0.000141	0.0624	CrCbGaD
Brompheniramine—Promazine—HTR2A—Alzheimer's disease	0.000133	0.0589	CrCbGaD
Brompheniramine—CHRM5—Signaling Pathways—INS—Alzheimer's disease	9.19e-06	0.000104	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—LPL—Alzheimer's disease	9.08e-06	0.000102	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—LPL—Alzheimer's disease	9.06e-06	0.000102	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CALM1—Alzheimer's disease	9.06e-06	0.000102	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCL2—Alzheimer's disease	9.04e-06	0.000102	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—LPL—Alzheimer's disease	9.03e-06	0.000102	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	9.03e-06	0.000102	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—APOE—Alzheimer's disease	9.03e-06	0.000102	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—LPL—Alzheimer's disease	9.01e-06	0.000102	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—MEF2C—Alzheimer's disease	8.98e-06	0.000101	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—BCHE—Alzheimer's disease	8.97e-06	0.000101	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—MEF2C—Alzheimer's disease	8.95e-06	0.000101	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CAV1—Alzheimer's disease	8.94e-06	0.000101	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—MEF2C—Alzheimer's disease	8.93e-06	0.000101	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—ABCA1—Alzheimer's disease	8.92e-06	0.000101	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—LPL—Alzheimer's disease	8.92e-06	0.000101	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—BCHE—Alzheimer's disease	8.9e-06	0.0001	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IGF1—Alzheimer's disease	8.89e-06	0.0001	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—MEF2C—Alzheimer's disease	8.84e-06	9.97e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—PRKCG—Alzheimer's disease	8.81e-06	9.94e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—PRKCG—Alzheimer's disease	8.78e-06	9.9e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—PRKCG—Alzheimer's disease	8.76e-06	9.87e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—TPI1—Alzheimer's disease	8.68e-06	9.79e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CHAT—Alzheimer's disease	8.68e-06	9.79e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—PRKCG—Alzheimer's disease	8.67e-06	9.78e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PPARGC1A—Alzheimer's disease	8.62e-06	9.71e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NGF—Alzheimer's disease	8.58e-06	9.68e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—HMOX1—Alzheimer's disease	8.58e-06	9.67e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NGF—Alzheimer's disease	8.56e-06	9.65e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NGF—Alzheimer's disease	8.53e-06	9.62e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	8.47e-06	9.55e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NGF—Alzheimer's disease	8.45e-06	9.52e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—NOS3—Alzheimer's disease	8.41e-06	9.49e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PLCB1—Alzheimer's disease	8.39e-06	9.46e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCR5—Alzheimer's disease	8.35e-06	9.42e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—MTHFR—Alzheimer's disease	8.34e-06	9.41e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—MAOB—Alzheimer's disease	8.33e-06	9.39e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCR5—Alzheimer's disease	8.32e-06	9.39e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCR5—Alzheimer's disease	8.3e-06	9.36e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	8.23e-06	9.28e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCR5—Alzheimer's disease	8.22e-06	9.27e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	8.21e-06	9.25e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—HTR2A—Alzheimer's disease	8.17e-06	9.21e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—MTHFR—Alzheimer's disease	8.17e-06	9.21e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—HTR2A—Alzheimer's disease	8.15e-06	9.18e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—ABCA1—Alzheimer's disease	8.14e-06	9.17e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—HTR2A—Alzheimer's disease	8.12e-06	9.16e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—NOS3—Alzheimer's disease	8.06e-06	9.09e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—HTR2A—Alzheimer's disease	8.04e-06	9.07e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	8.02e-06	9.04e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—PPARG—Alzheimer's disease	7.86e-06	8.87e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—LPL—Alzheimer's disease	7.84e-06	8.84e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CALM1—Alzheimer's disease	7.79e-06	8.79e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—APOE—Alzheimer's disease	7.77e-06	8.76e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—A2M—Alzheimer's disease	7.74e-06	8.73e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—INS—Alzheimer's disease	7.71e-06	8.7e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CAV1—Alzheimer's disease	7.69e-06	8.68e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PPARGC1A—Alzheimer's disease	7.69e-06	8.67e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—HMOX1—Alzheimer's disease	7.66e-06	8.63e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CALM1—Alzheimer's disease	7.63e-06	8.61e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CALM1—Alzheimer's disease	7.62e-06	8.6e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—APOE—Alzheimer's disease	7.61e-06	8.58e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CALM1—Alzheimer's disease	7.6e-06	8.57e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—LEP—Alzheimer's disease	7.6e-06	8.57e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—APOE—Alzheimer's disease	7.6e-06	8.57e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CALM1—Alzheimer's disease	7.58e-06	8.54e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—APOE—Alzheimer's disease	7.57e-06	8.54e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—LEP—Alzheimer's disease	7.57e-06	8.54e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—LEP—Alzheimer's disease	7.55e-06	8.51e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—APOE—Alzheimer's disease	7.55e-06	8.51e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CAV1—Alzheimer's disease	7.54e-06	8.5e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CAV1—Alzheimer's disease	7.53e-06	8.49e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CAV1—Alzheimer's disease	7.5e-06	8.46e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CALM1—Alzheimer's disease	7.5e-06	8.46e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CAV1—Alzheimer's disease	7.48e-06	8.43e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—LEP—Alzheimer's disease	7.48e-06	8.43e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—APOE—Alzheimer's disease	7.48e-06	8.43e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CAV1—Alzheimer's disease	7.41e-06	8.35e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—ESR1—Alzheimer's disease	7.25e-06	8.18e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—ESR1—Alzheimer's disease	7.23e-06	8.15e-05	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—AKT1—Alzheimer's disease	7.21e-06	8.13e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—ESR1—Alzheimer's disease	7.21e-06	8.13e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—F2—Alzheimer's disease	7.16e-06	8.08e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CASP3—Alzheimer's disease	7.14e-06	8.05e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—F2—Alzheimer's disease	7.14e-06	8.05e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—ESR1—Alzheimer's disease	7.14e-06	8.05e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—F2—Alzheimer's disease	7.12e-06	8.03e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—IL6—Alzheimer's disease	7.1e-06	8e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	7.07e-06	7.98e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—MTHFR—Alzheimer's disease	7.06e-06	7.96e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—F2—Alzheimer's disease	7.05e-06	7.95e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	7.04e-06	7.94e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PPARGC1A—Alzheimer's disease	7.01e-06	7.91e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NOTCH1—Alzheimer's disease	7.01e-06	7.91e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—LPL—Alzheimer's disease	7e-06	7.89e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NOTCH1—Alzheimer's disease	6.99e-06	7.88e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—HMOX1—Alzheimer's disease	6.98e-06	7.87e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NOTCH1—Alzheimer's disease	6.97e-06	7.86e-05	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—AKT1—Alzheimer's disease	6.9e-06	7.79e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NOTCH1—Alzheimer's disease	6.9e-06	7.78e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CASP3—Alzheimer's disease	6.84e-06	7.71e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—IL6—Alzheimer's disease	6.8e-06	7.66e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—PPARG—Alzheimer's disease	6.76e-06	7.63e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—NOS3—Alzheimer's disease	6.76e-06	7.63e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—ACHE—Alzheimer's disease	6.73e-06	7.59e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	6.66e-06	7.51e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—INS—Alzheimer's disease	6.63e-06	7.48e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—PPARG—Alzheimer's disease	6.63e-06	7.47e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CALM1—Alzheimer's disease	6.6e-06	7.44e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—GSK3B—Alzheimer's disease	6.58e-06	7.42e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—APOE—Alzheimer's disease	6.58e-06	7.41e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—MAPK8—Alzheimer's disease	6.57e-06	7.4e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—GSK3B—Alzheimer's disease	6.56e-06	7.39e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—AKT1—Alzheimer's disease	6.55e-06	7.38e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—GSK3B—Alzheimer's disease	6.54e-06	7.37e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CREB1—Alzheimer's disease	6.53e-06	7.36e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CAV1—Alzheimer's disease	6.51e-06	7.35e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CREB1—Alzheimer's disease	6.51e-06	7.34e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—INS—Alzheimer's disease	6.5e-06	7.33e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—INS—Alzheimer's disease	6.49e-06	7.32e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CREB1—Alzheimer's disease	6.48e-06	7.31e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—GSK3B—Alzheimer's disease	6.47e-06	7.3e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—INS—Alzheimer's disease	6.47e-06	7.29e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—INS—Alzheimer's disease	6.45e-06	7.27e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—LPL—Alzheimer's disease	6.44e-06	7.26e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CREB1—Alzheimer's disease	6.42e-06	7.24e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—INS—Alzheimer's disease	6.39e-06	7.2e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCL2—Alzheimer's disease	6.39e-06	7.2e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—LPL—Alzheimer's disease	6.38e-06	7.2e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCL2—Alzheimer's disease	6.37e-06	7.18e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCL2—Alzheimer's disease	6.35e-06	7.15e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	6.31e-06	7.12e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—ENO1—Alzheimer's disease	6.31e-06	7.12e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—MTHFR—Alzheimer's disease	6.3e-06	7.11e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—MAPK8—Alzheimer's disease	6.29e-06	7.09e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCL2—Alzheimer's disease	6.28e-06	7.09e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IGF1—Alzheimer's disease	6.28e-06	7.08e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—AKT1—Alzheimer's disease	6.27e-06	7.07e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IGF1—Alzheimer's disease	6.26e-06	7.06e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IGF1—Alzheimer's disease	6.24e-06	7.03e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	6.19e-06	6.98e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—PTGS2—Alzheimer's disease	6.19e-06	6.97e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IGF1—Alzheimer's disease	6.18e-06	6.97e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—VEGFA—Alzheimer's disease	6.06e-06	6.84e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CALM1—Alzheimer's disease	5.89e-06	6.64e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—APOE—Alzheimer's disease	5.87e-06	6.62e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—BCHE—Alzheimer's disease	5.87e-06	6.61e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—NOS3—Alzheimer's disease	5.82e-06	6.56e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CAV1—Alzheimer's disease	5.81e-06	6.56e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—VEGFA—Alzheimer's disease	5.8e-06	6.55e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	5.8e-06	6.54e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—MTHFR—Alzheimer's disease	5.75e-06	6.48e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PPARG—Alzheimer's disease	5.73e-06	6.46e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—NOS3—Alzheimer's disease	5.7e-06	6.43e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NOS3—Alzheimer's disease	5.69e-06	6.42e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NOS3—Alzheimer's disease	5.67e-06	6.4e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NOS3—Alzheimer's disease	5.66e-06	6.38e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—INS—Alzheimer's disease	5.62e-06	6.33e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NOS3—Alzheimer's disease	5.6e-06	6.31e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—TGFB1—Alzheimer's disease	5.56e-06	6.27e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	5.54e-06	6.24e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CALM1—Alzheimer's disease	5.42e-06	6.11e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—APOE—Alzheimer's disease	5.4e-06	6.09e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CALM1—Alzheimer's disease	5.37e-06	6.06e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	5.37e-06	6.05e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—APOE—Alzheimer's disease	5.35e-06	6.03e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CAV1—Alzheimer's disease	5.35e-06	6.03e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—TGFB1—Alzheimer's disease	5.33e-06	6.01e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—PTGS2—Alzheimer's disease	5.32e-06	6e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CAV1—Alzheimer's disease	5.3e-06	5.98e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—PTGS2—Alzheimer's disease	5.21e-06	5.88e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PPARG—Alzheimer's disease	5.11e-06	5.76e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—INS—Alzheimer's disease	5.01e-06	5.65e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—NOS3—Alzheimer's disease	4.93e-06	5.55e-05	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—AKT1—Alzheimer's disease	4.88e-06	5.5e-05	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—AKT1—Alzheimer's disease	4.86e-06	5.48e-05	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—AKT1—Alzheimer's disease	4.85e-06	5.46e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CASP3—Alzheimer's disease	4.83e-06	5.45e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CASP3—Alzheimer's disease	4.82e-06	5.43e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CASP3—Alzheimer's disease	4.8e-06	5.41e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—IL6—Alzheimer's disease	4.8e-06	5.41e-05	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—AKT1—Alzheimer's disease	4.8e-06	5.41e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—IL6—Alzheimer's disease	4.79e-06	5.4e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—IL6—Alzheimer's disease	4.77e-06	5.38e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CASP3—Alzheimer's disease	4.75e-06	5.36e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—IL6—Alzheimer's disease	4.72e-06	5.33e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PPARG—Alzheimer's disease	4.7e-06	5.3e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PPARG—Alzheimer's disease	4.66e-06	5.26e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	4.62e-06	5.21e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—INS—Alzheimer's disease	4.61e-06	5.2e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	4.6e-06	5.19e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—TP53—Alzheimer's disease	4.58e-06	5.16e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—INS—Alzheimer's disease	4.57e-06	5.15e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PTGS2—Alzheimer's disease	4.51e-06	5.08e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—MAPK8—Alzheimer's disease	4.44e-06	5.01e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—AKT1—Alzheimer's disease	4.43e-06	4.99e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—MAPK8—Alzheimer's disease	4.43e-06	4.99e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—AKT1—Alzheimer's disease	4.41e-06	4.98e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—MAPK8—Alzheimer's disease	4.41e-06	4.98e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—AKT1—Alzheimer's disease	4.4e-06	4.96e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—NOS3—Alzheimer's disease	4.4e-06	4.96e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—TP53—Alzheimer's disease	4.39e-06	4.95e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—MAPK8—Alzheimer's disease	4.37e-06	4.93e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—AKT1—Alzheimer's disease	4.36e-06	4.91e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—LPL—Alzheimer's disease	4.21e-06	4.75e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IL6—Alzheimer's disease	4.19e-06	4.73e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—VEGFA—Alzheimer's disease	4.1e-06	4.62e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—VEGFA—Alzheimer's disease	4.09e-06	4.61e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—VEGFA—Alzheimer's disease	4.07e-06	4.59e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—NOS3—Alzheimer's disease	4.04e-06	4.56e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—VEGFA—Alzheimer's disease	4.03e-06	4.55e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PTGS2—Alzheimer's disease	4.02e-06	4.53e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IL6—Alzheimer's disease	4.01e-06	4.53e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—NOS3—Alzheimer's disease	4.01e-06	4.52e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—AKT1—Alzheimer's disease	3.87e-06	4.36e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	3.79e-06	4.27e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TGFB1—Alzheimer's disease	3.76e-06	4.24e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TGFB1—Alzheimer's disease	3.75e-06	4.23e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TGFB1—Alzheimer's disease	3.74e-06	4.22e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—AKT1—Alzheimer's disease	3.7e-06	4.18e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TGFB1—Alzheimer's disease	3.7e-06	4.18e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	3.7e-06	4.17e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PTGS2—Alzheimer's disease	3.67e-06	4.13e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CALM1—Alzheimer's disease	3.54e-06	3.99e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—APOE—Alzheimer's disease	3.53e-06	3.98e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CAV1—Alzheimer's disease	3.5e-06	3.94e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—AKT1—Alzheimer's disease	3.11e-06	3.51e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TP53—Alzheimer's disease	3.1e-06	3.49e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TP53—Alzheimer's disease	3.09e-06	3.48e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TP53—Alzheimer's disease	3.08e-06	3.47e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PPARG—Alzheimer's disease	3.07e-06	3.47e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TP53—Alzheimer's disease	3.05e-06	3.44e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—INS—Alzheimer's disease	3.01e-06	3.4e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IL6—Alzheimer's disease	2.84e-06	3.2e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IL6—Alzheimer's disease	2.83e-06	3.19e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IL6—Alzheimer's disease	2.82e-06	3.18e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IL6—Alzheimer's disease	2.79e-06	3.15e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—AKT1—Alzheimer's disease	2.67e-06	3.02e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—NOS3—Alzheimer's disease	2.64e-06	2.98e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—AKT1—Alzheimer's disease	2.62e-06	2.95e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—AKT1—Alzheimer's disease	2.62e-06	2.95e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—AKT1—Alzheimer's disease	2.61e-06	2.94e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—AKT1—Alzheimer's disease	2.6e-06	2.93e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—AKT1—Alzheimer's disease	2.57e-06	2.9e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	2.42e-06	2.73e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—AKT1—Alzheimer's disease	2.26e-06	2.55e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—AKT1—Alzheimer's disease	2.02e-06	2.28e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—AKT1—Alzheimer's disease	1.86e-06	2.1e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—AKT1—Alzheimer's disease	1.84e-06	2.08e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—AKT1—Alzheimer's disease	1.22e-06	1.37e-05	CbGpPWpGaD
